Mr. Patrick J Flynn, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 210 Jones Rd, Suite 25, Falmouth, MA 02540 Phone: 508-540-9771 Fax: 508-540-3158 |
Mr. Peter S Hopewood, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 210 Jones Rd, Suite 25, Falmouth, MA 02540 Phone: 508-540-9771 Fax: 508-540-3158 |
Mr. Garry L Brake, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 210 Jones Rd, Suite 2 5, Falmouth, MA 02540 Phone: 508-540-9771 Fax: 508-540-3158 |
James B Knox, MD Surgery - Vascular Surgery Medicare: Accepting Medicare Assignments Practice Location: 90 Ter Heun Drive, Suite 300, Falmouth, MA 02540 Phone: 508-540-0604 Fax: 508-457-0129 |
Kenneth A Heisler, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 78 Main Street, Falmouth, MA 02540 Phone: 508-548-8317 Fax: 508-548-7407 |
Mr. Alan Edwin Cordts, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 78 Main Street, Falmouth, MA 02540 Phone: 508-367-3937 Fax: 508-548-7407 |
Terence Jean Christle, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 15 Garrison Rd, Falmouth, MA 02540 Phone: 508-540-0961 |
News Archive
Millions of low-income people could be required to pay more for health care under a proposed federal policy that would give states more freedom to impose co-payments and other charges on Medicaid patients.
Today, 120 fourth-year medical students at Penn State College of Medicine learned where they will spend their residencies in an annual tradition known as Match Day. A similar scene played out with fourth-year students at medical schools across the country.
Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has been issued U.S. Patent No. 7,883,872 entitled, Construction of Highly Efficient Cellulase Compositions for Enzymatic Hydrolysis of Cellulose, by the United States Patent and Trademark Office ("USPTO").
In a study of nearly 650 people with the eye disease age-related macular degeneration (AMD), half still had vision 20/40 or better, typically good enough to drive or to read standard print, after five years of treatment with anti-VEGF drugs that are injected into the eye. The authors of the study, funded by the National Eye Institute (NEI) at the National Institutes of Health, say those outcomes would have been unimaginable about 10 years ago, prior to the drugs' availability.
› Verified 1 days ago